A recent clinical trial assessing the safety and efficacy of brodalumab (a fully human anti–IL-17 receptor A monoclonal antibody) was carried out using eight SSc patients; the trial demonstrated its safety and that the blockage of the IL-17 signaling pathway resulted in the improvement of skin fibrosis, a decrease of the mRSS, a reduction in digital ulcers, and increased Treg/Th17 ratios in SSc patients [73]. The gene discussed is IL17A; the disease is systemic sclerosis.